Advanced search
Publication Cover
International Journal of Neuroscience Volume 130, 2020 - Issue 12
Submit an article Journal homepage
462
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial

Sven G MeuthDepartment of Neurology with Institute of Translational Neurology, University Hospital Munster, Munster, Germany; Correspondence[email protected]
View further author information
,
Thomas HenzePraxis Für Neurologie, Regensburg, Germany; View further author information
,
Ute EssnerO. Meany Consultancy GmbH, Hamburg, Germany; View further author information
,
Christiane TrompkeR&D, Almirall Hermal GmbH, Reinbek, Germany; View further author information
&
Carlos Vila SilvánGlobal Medical Affairs, Almirall S.A, Barcelona, SpainView further author information
Pages 1199-1205 | Received 04 Nov 2019, Accepted 03 Feb 2020, Published online: 01 Mar 2020

References

  • Bensmail D, Vermersch P. Epidemiology and clinical assessment of spasticity in multiple sclerosis. Rev Neurol (Paris) 2012;168(Suppl 3):S45–S50.
  • Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15(3):146–158.
  • Bethoux F, Marrie RA. A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis. Patient 2016;9(6):537–546.
  • Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis - Clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154–162.
  • Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: The CANDLE study. Int J Neurosci. 2013;123(12):850–858.
  • Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016;22(11):1386–1396.
  • Henze T, Feneberg W, Flachenecker P, et al. What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. Nervenarzt 2017;88(12):1428–1434.
  • eMC Sativex Oromucosal Spray SPC. 2018. [cited 2019 September 5]. Available from: https://www.medicines.org.uk/emc/history/23262.
  • Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo- controlled study on 160 patients. Mult Scler. 2004;10(4):434–441.
  • Collin C, Davies P, Mutiboko IK, et al.; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296.
  • Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–459.
  • Novotna A, Mares J, Ratcliffe S, et al.; The Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel- group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131.
  • Markovà J, Essner U, Akmaz B, et al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129(2):119–128.
  • Lucchinetti C, Brack W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.